A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer.
about
Penile metastasis from primary transitional cell carcinoma of the renal pelvis: first manifestation of systemic spreadInhibiting Immune Checkpoints for the Treatment of Bladder CancerRole of systemic chemotherapy in urothelial urinary bladder cancerCytotoxic and DNA-targeted therapy in urothelial cancer: have we squeezed the lemon enough?Systemic therapy for bladder cancer finally comes into a new age.A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urotheliumGemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens.Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen.The efficacy and safety of gemcitabine plus cisplatin regimen for patients with advanced urothelial carcinoma after failure of M-VAC regimen.Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma.Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.Comparison of single agent versus combined chemotherapy in previously treated patients with advanced urothelial carcinoma: a meta-analysis.A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma.Complete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: a case report.Chemotherapy and management of bladder tumours.Progress in the management of metastatic bladder cancer.Recent advances in bladder cancer chemotherapy.Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice.First- and second-line therapy for metastatic urothelial carcinoma of the bladderCurrent therapeutic strategies for invasive and metastatic bladder cancer.Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinomaIntravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option.Role of gemcitabine in cancer therapy.Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study.A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimenIntravesical treatments of bladder cancer: review.Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer.Systemic therapy for metastatic urothelial carcinoma.Current optimal chemotherapy for advanced urothelial cancer.Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysisThe high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents.Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium.Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.Novel targeted agents for the treatment of bladder cancer: translating laboratory advances into clinical application.Vinflunine in the treatment of advanced bladder cancer.Treatment of metastatic renal cell carcinoma and renal pelvic cancer.Current chemotherapeutic strategies against bladder cancer.Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma.Current treatment of metastatic bladder cancer and future directions.
P2860
Q24792000-50DB2AB1-CD75-4CF7-AB61-5C7AE635F554Q26744758-2ED8D789-B46F-456A-88E9-103BE9BF1EF7Q27010323-D6F12FB5-BB71-44A9-BECF-942166A0A44BQ27026717-D1CDE87F-600F-4D53-9947-DB02FD5C690EQ30249047-0CEED7CA-B098-4AEB-A692-B36CDDC88B93Q33287243-4E105A4D-7EDA-4722-8644-AED0B60F7806Q33344322-E2DF4ED9-3A0C-43C0-8426-3AF40171F278Q33369395-C0F5F695-ADE8-4960-8BBF-1BD5D1E3243AQ33394213-753493C2-E40F-40FB-8B85-924F405FA4CBQ33394627-7DCFB943-8517-464A-91D2-0F9C4EC1C128Q33398722-20DA89F3-C877-4D64-B6EF-C575E4411124Q33399928-469A353A-6317-4216-8E8C-C3C3B8A55EEFQ33431220-5F58E275-B620-4874-9D5B-A00B288D5BADQ33621281-E3EA0253-7211-44D5-8EBB-C889FDAA23C4Q33638615-E7DCBC5E-1032-4083-9914-7AAB1B361ECAQ33874502-20C33FEA-9557-4FC3-A606-35650326C5B7Q33968726-5FADC679-A072-4555-8AB1-70CA49DED4E3Q34211041-E4B70F7C-E6B9-4313-AFE8-08E1CD95CBFFQ34438928-1E4403C1-78ED-45B5-9F06-D980DDCC008AQ34541463-75D67A01-6956-4685-8406-25910A21B20DQ35128721-6520CBF9-0FE9-4FD6-A0EA-F26BCF9BDE39Q36267685-28BA29F3-7372-4259-BEB0-F9EAE8212676Q36286371-2899B7EF-C35D-478D-9313-55E17D3BF94EQ36429373-6538331B-117D-454C-B503-9FEF065C4181Q36610731-BADD814E-6CAD-469F-B3B0-DA0BBC00209DQ36614243-92285916-1C70-4135-8D1E-02C965C99B54Q36738254-4A161635-26C3-4BF8-9027-06D60770506EQ36953789-A7468C6B-FADF-45BB-8C15-95EFFED6718DQ37028356-1DD0C99A-67EA-4563-94AB-02FE1D361288Q37038897-26153F15-4369-484D-BCC6-D7ABA747F81CQ37108266-BD2D461E-242E-47C8-93B1-958BFD361A22Q37187791-24972EDF-F3B5-46EE-AECD-3F9D3E9DA005Q37389950-FE9EF9B0-6270-416A-94F7-A052CD1B8B17Q37474079-5863A601-CF1A-4DDD-9837-708325A9CBBFQ37770131-539E3E25-FFEA-49D3-B115-8EA08B23E3C8Q37821892-DE3A57A9-018D-4A8F-A5D9-6AF72C97C5E8Q37863582-5D634E15-D6E9-4FCA-AB34-3B348867EF1DQ37888549-98F1643D-3367-432A-8508-5BB96B25D37DQ37896172-67647BB5-A9CE-4A68-8ECF-153F794FE3ACQ37960909-62905BE8-63FF-4533-8221-180EA4BB3DDE
P2860
A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer.
description
1998 nî lūn-bûn
@nan
1998 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
A phase II study of gemcitabin ...... ative Group on Bladder Cancer.
@ast
A phase II study of gemcitabin ...... ative Group on Bladder Cancer.
@en
type
label
A phase II study of gemcitabin ...... ative Group on Bladder Cancer.
@ast
A phase II study of gemcitabin ...... ative Group on Bladder Cancer.
@en
prefLabel
A phase II study of gemcitabin ...... ative Group on Bladder Cancer.
@ast
A phase II study of gemcitabin ...... ative Group on Bladder Cancer.
@en
P2093
P1476
A phase II study of gemcitabin ...... ative Group on Bladder Cancer.
@en
P2093
C F Pollera
C Gridelli
G L Frassineti
G Luporini
P304
P356
10.1016/S0959-8049(98)00030-6
P577
1998-07-01T00:00:00Z